Kiadis Pharma and The Leukemia & Lymphoma Society strength­en part­ner­ship around the devel­op­ment of ATIR101™ in ALL and AML patients

~ LLS makes sec­ond equi­ty invest­ment in Kiadis Pharma for the Phase II devel­op­ment ~

Amsterdam, The Netherlands, July 11, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell immunother­a­py treat­ments for blood can­cers and inher­it­ed blood dis­or­ders, today announces that its part­ner­ship with The Leukemia & Lymphoma Society (LLS), the world’s largest vol­un­tary health agency focused on blood can­cers, has been strength­ened with a sec­ond equi­ty invest­ment by LLS into the devel­op­ment of Kiadis Pharma’s lead prod­uct ATIR101™.
LLS ini­tial­ly invest­ed approx­i­mate­ly US$1 mil­lion in February 2016 through an equi­ty invest­ment via its Therapy Acceleration Program (TAP), a strate­gic ini­tia­tive to part­ner direct­ly with biotech­nol­o­gy com­pa­nies to help accel­er­ate the devel­op­ment of promis­ing ther­a­pies. This sec­ond invest­ment will now also be used to finance Kiadis Pharma’s sec­ond ongo­ing Phase II tri­al in leukemia patients which the Company then intends to con­tin­ue into a ran­dom­ized con­trolled Phase III piv­otal study on track to start lat­er this year. The ongo­ing Phase II tri­al is inves­ti­gat­ing the repeat­ed dos­ing of ATIR101™ as an adjunc­tive treat­ment to a T-cell deplet­ed hap­loiden­ti­cal hematopoi­et­ic stem cell trans­plan­ta­tion (HSCT) (donor cells from a half-matched relat­ed donor) in adult patients with acute myeloid leukemia (AML) or acute lym­phoblas­tic leukemia (ALL). The tri­al (CR-AIR-008; NCT02500550 / EudraCT 2015-002821-20) is con­duct­ed under an IND of the United States Food and Drug Administration and is set up to enroll patients in the United States as well as oth­er coun­tries, includ­ing Canada, Belgium, Germany and the United Kingdom.
The sec­ond fund­ing by LLS has tak­en place through an equi­ty invest­ment of approx­i­mate­ly US$750,000 and a total of 67,020 shares will be issued to LLS.
Manfred Rüdiger, PhD, Chief Executive Officer of Kiadis Pharma, com­ment­ed: “We are delight­ed that LLS has made anoth­er sig­nif­i­cant con­tri­bu­tion to the devel­op­ment of our lead prod­uct ATIR101™ and invest­ed fur­ther in Kiadis Pharma. This is again a strong sign of con­fi­dence in what we do and our goal remains to be to bring this impor­tant prod­uct to patients as quick­ly as pos­si­ble.”
Louis J. DeGennaro, Ph.D., LLS’s President and CEO, added: “Kiadis Pharma’s ATIR101™ shows great promise in fight­ing life-threat­en­ing infec­tions and graft ver­sus host dis­ease fol­low­ing stem cell trans­plan­ta­tions. LLS is very pleased to be increas­ing its lev­el of sup­port for this pro­gram which we hope will improve out­comes for patients with blood can­cers.”

Leave a Reply

Your email address will not be published. Required fields are marked *